GLYBURIDE Drug Patent Profile
✉ Email this page to a colleague
When do Glyburide patents expire, and what generic alternatives are available?
Glyburide is a drug marketed by Actavis Elizabeth, Aurobindo Pharma, Cadila Pharms Ltd, Chartwell Rx, Epic Pharma Llc, Heritage, Impax Labs Inc, Orient Pharma Co Ltd, Teva, Zydus Pharms, Hikma, Natco Pharma, Sanofi Aventis Us, and Strides Pharma. and is included in twenty-three NDAs.
The generic ingredient in GLYBURIDE is glyburide; metformin hydrochloride. There are twenty drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the glyburide; metformin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Glyburide
A generic version of GLYBURIDE was approved as glyburide; metformin hydrochloride by IMPAX LABS INC on February 18th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GLYBURIDE?
- What are the global sales for GLYBURIDE?
- What is Average Wholesale Price for GLYBURIDE?
Summary for GLYBURIDE
| US Patents: | 0 |
| Applicants: | 14 |
| NDAs: | 23 |
| Finished Product Suppliers / Packagers: | 19 |
| Raw Ingredient (Bulk) Api Vendors: | 152 |
| Clinical Trials: | 74 |
| Patent Applications: | 4,327 |
| Drug Prices: | Drug price information for GLYBURIDE |
| Drug Sales Revenues: | Drug sales revenues for GLYBURIDE |
| What excipients (inactive ingredients) are in GLYBURIDE? | GLYBURIDE excipients list |
| DailyMed Link: | GLYBURIDE at DailyMed |
Recent Clinical Trials for GLYBURIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Maryland, Baltimore | Phase 2 |
| University of Kentucky | Phase 1 |
| Medical College of Wisconsin | Phase 4 |
Pharmacology for GLYBURIDE
| Drug Class | Sulfonylurea |
Medical Subject Heading (MeSH) Categories for GLYBURIDE
US Patents and Regulatory Information for GLYBURIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | GLYBURIDE (MICRONIZED) | glyburide | TABLET;ORAL | 020055-003 | Mar 8, 2000 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Chartwell Rx | GLYBURIDE (MICRONIZED) | glyburide | TABLET;ORAL | 075174-002 | Jun 22, 1998 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva | GLYBURIDE (MICRONIZED) | glyburide | TABLET;ORAL | 074686-004 | Apr 20, 1999 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
